- TOTAL REVENUE OF $247.6
MILLION FOR THE YEAR ENDED 2023 VS $219.3 MILLION IN 2022, AN INCREASE OF
13%
- HOSPITAL DIVISION OPERATING INCOME OF $36.3 MILLION FOR YEAR ENDED 2023 VS $15.0 MILLION IN 2022, AN INCREASE OF
142%
- NET CASH FROM OPERATING ACTIVITIES OF $1.3 MILLION FOR THE YEAR ENDED 2023
- CONTINUED FOCUS ON INCREASED CASH FLOW THROUGH REDUCTION
IN OPERATING EXPENSES AND PORTFOLIO OPTIMIZATION
HOUSTON, March 28,
2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex
Health" or the "Company") (NASDAQ: NUTX), a physician-led,
technology-enabled integrated healthcare delivery system comprised
of 20 state-of-the-art micro hospitals in eight states and primary
care-centric, risk-bearing physician networks, today announced
fourth quarter and fiscal year 2023 financial results for the
twelve months ended December 31,
2023.
Financial Highlights for the Three Months Ended December 31, 2023:
- Total revenue of $69.7 million as
compared to total revenue of $53.7
million for the three months ended December 31, 2022, an increase of approximately
30%.
- Net loss attributable to Nutex Health Inc. of $31.6 million (including a non-cash asset
impairment charge of $29.1 million
and a $1.1 million goodwill
impairment charge for hospital closures) as compared to net loss
attributable to Nutex Health Inc. of $14.8
million for the three months ended December 31, 2022.
- Adjusted EBITDA of $3.1 million
as compared to Adjusted EBITDA of negative $5.9 million for the three months ended
December 31, 2022.
Financial Highlights for the Year Ended December 31, 2023:
- Total revenue of $247.6 million
as compared to total revenue of $219.3
million for the year ended December
31, 2022.
- Net loss attributable to Nutex Health Inc. of $45.8 million (including a non-cash asset
impairment charge of $29.1 million
and a $1.1 million goodwill
impairment charge for hospital closures) as compared to net loss
attributable to Nutex Health Inc. of $424.8
million (including a non-cash goodwill impairment charge of
$398.1 million) for the year ended
December 31, 2022.
- Adjusted EBITDA of $10.8 million
as compared to Adjusted EBITDA of $12.6
million for the year ended December
31, 2022.
- Net cash from operating activities of $1.3 million.
- As of December 31, 2023, the
Company had total assets of $398.2
million, including cash and cash equivalents of $22.0 million.
Note: EBITDA and Adjusted EBITDA are non-GAAP financial
metrics. A reconciliation of non-GAAP to GAAP measures is
included below in this earnings release.
"We are pleased to report 13% revenue growth, $10.8 million of Adjusted EBITDA and a 142%
increase in hospital division operating income to $36.3 million in 2023," stated Jon Bates, Chief Financial Officer of Nutex
Health.
"We had a solid 4th Quarter in 2023. In January
of 2024, our management team and Board of Directors initiated a
streamlined strategic plan that included a targeted reduction in
annual cash operating expenses as well as a more focused allocation
of resources and portfolio optimization. Some of these initiatives
have already been executed while others are in the process of being
implemented. Our goal for 2024 is to continue to be the
leader and innovator in our industry, and to provide a very unique
platform for selected growth opportunities," stated Tom Vo, M.D., MBA, Chairman and Chief Executive
Officer of Nutex Health.
"We are intensely focused on our goal to deliver profitability
on a net income basis to our investors. We believe that we
are well positioned to improve our financial performance over the
medium and long-term," stated Warren
Hosseinion, M.D., President of Nutex Health.
For more details on the Company's Fourth Quarter and Fiscal Year
2023 financial results, please refer to our Annual Report on Form
10-K filed with the U.S. Securities & Exchange Commission and
accessible at www.sec.gov.
|
NUTEX HEALTH
INC.
|
|
CONSOLIDATED BALANCE
SHEETS
|
|
(Unaudited)
|
|
|
December 31,
|
|
|
2023
|
|
2022
|
|
Assets
|
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
$
|
22,002,056
|
|
$
|
34,255,264
|
|
Accounts
receivable
|
|
|
58,624,301
|
|
|
57,777,386
|
|
Accounts receivable -
related parties
|
|
|
4,152,068
|
|
|
538,183
|
|
Inventories
|
|
|
3,390,584
|
|
|
3,533,285
|
|
Prepaid expenses and
other current assets
|
|
|
2,679,394
|
|
|
1,869,806
|
|
Total current
assets
|
|
|
90,848,403
|
|
|
97,973,924
|
|
Property and equipment,
net
|
|
|
81,387,649
|
|
|
82,094,352
|
|
Operating right-of-use
assets
|
|
|
11,853,082
|
|
|
20,466,632
|
|
Financing right-of-use
assets
|
|
|
176,146,329
|
|
|
192,591,624
|
|
Intangible assets,
net
|
|
|
20,512,636
|
|
|
21,191,390
|
|
Goodwill,
net
|
|
|
17,066,263
|
|
|
17,010,637
|
|
Other assets
|
|
|
431,135
|
|
|
423,426
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
398,245,497
|
|
$
|
431,751,985
|
|
|
|
|
|
|
|
|
Liabilities and Equity
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$
|
18,899,196
|
|
$
|
23,614,387
|
|
Accounts payable -
related parties
|
|
|
6,382,197
|
|
|
3,915,661
|
|
Lines of
credit
|
|
|
3,371,676
|
|
|
2,623,479
|
|
Current portion of
long-term debt
|
|
|
10,808,721
|
|
|
12,546,097
|
|
Operating lease
liabilities, current portion
|
|
|
1,579,987
|
|
|
1,703,014
|
|
Financing lease
liabilities, current portion
|
|
|
4,315,979
|
|
|
4,219,518
|
|
Accrued expenses and
other current liabilities
|
|
|
12,955,296
|
|
|
6,240,813
|
|
Total current
liabilities
|
|
|
58,313,052
|
|
|
54,862,969
|
|
Long-term debt,
net
|
|
|
26,314,733
|
|
|
23,051,152
|
|
Operating lease
liabilities, net
|
|
|
15,479,639
|
|
|
19,438,497
|
|
Financing lease
liabilities, net
|
|
|
213,886,213
|
|
|
203,619,756
|
|
Deferred tax
liabilities
|
|
|
5,145,754
|
|
|
10,452,211
|
|
Total
liabilities
|
|
|
319,139,391
|
|
|
311,424,585
|
|
|
|
|
|
|
|
|
Commitments and
contingencies (Note 10)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity:
|
|
|
|
|
|
|
|
Common stock, $0.001
par value; 950,000,000 shares authorized; 676,679,911 and
650,223,840 shares issued and outstanding as of
December 31, 2023 and December 31, 2022,
respectively
|
|
|
676,680
|
|
|
650,224
|
|
Additional paid-in
capital
|
|
|
469,849,049
|
|
|
458,498,402
|
|
Accumulated
deficit
|
|
|
(409,072,539)
|
|
|
(363,285,925)
|
|
Nutex Health Inc.
equity
|
|
|
61,453,190
|
|
|
95,862,701
|
|
Noncontrolling
interests
|
|
|
17,652,916
|
|
|
24,464,699
|
|
Total equity
|
|
|
79,106,106
|
|
|
120,327,400
|
|
|
|
|
|
|
|
|
Total liabilities and
equity
|
|
$
|
398,245,497
|
|
$
|
431,751,985
|
|
NUTEX HEALTH
INC.
|
|
CONSOLIDATED
STATEMENTS OF OPERATIONS
|
|
(Unaudited)
|
|
|
|
Three months ended
December 31
|
|
Year ended December 31
|
|
|
2023
|
|
2022
|
|
2023
|
|
2022
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hospital
division
|
|
$
|
62,585,167
|
|
$
|
46,532,019
|
|
$
|
218,070,397
|
|
$
|
198,508,245
|
|
Population health
management division
|
|
|
7,084,306
|
|
|
7,192,054
|
|
|
29,575,919
|
|
|
20,786,061
|
|
Total
revenue
|
|
|
69,669,473
|
|
|
53,724,073
|
|
|
247,646,316
|
|
|
219,294,306
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating costs and
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payroll
|
|
|
28,807,419
|
|
|
26,466,650
|
|
|
108,377,938
|
|
|
111,785,110
|
|
Contract
services
|
|
|
14,377,128
|
|
|
9,809,286
|
|
|
42,349,982
|
|
|
35,913,441
|
|
Medical
supplies
|
|
|
3,402,926
|
|
|
2,791,779
|
|
|
14,151,140
|
|
|
12,118,893
|
|
Insurance
expense
|
|
|
-
|
|
|
2,284,377
|
|
|
-
|
|
|
-
|
|
Depreciation and
amortization
|
|
|
4,682,724
|
|
|
3,271,861
|
|
|
17,591,572
|
|
|
13,131,374
|
|
Other
|
|
|
5,185,964
|
|
|
8,569,796
|
|
|
30,401,513
|
|
|
30,923,750
|
|
Total operating
costs and expenses
|
|
|
56,456,161
|
|
|
53,193,749
|
|
|
212,872,145
|
|
|
203,872,568
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
|
|
13,213,312
|
|
|
530,324
|
|
|
34,774,171
|
|
|
15,421,738
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate and other
costs:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facilities closing
costs
|
|
|
-
|
|
|
-
|
|
|
217,266
|
|
|
-
|
|
Acquisition
costs
|
|
|
-
|
|
|
-
|
|
|
43,464
|
|
|
3,885,666
|
|
Stock-based
compensation
|
|
|
637,159
|
|
|
-
|
|
|
2,835,971
|
|
|
189,581
|
|
Impairment of
assets
|
|
|
29,082,203
|
|
|
-
|
|
|
29,082,203
|
|
|
-
|
|
Impairment of
goodwill
|
|
|
1,139,297
|
|
|
-
|
|
|
1,139,297
|
|
|
398,135,038
|
|
General and
administrative expenses
|
|
|
8,499,550
|
|
|
6,309,235
|
|
|
33,229,718
|
|
|
19,810,607
|
|
Total corporate
and other costs
|
|
|
39,358,209
|
|
|
6,309,235
|
|
|
66,547,919
|
|
|
422,020,892
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
income (loss)
|
|
|
(26,144,897)
|
|
|
(5,778,911)
|
|
|
(31,773,748)
|
|
|
(406,599,154)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense,
net
|
|
|
4,236,553
|
|
|
2,862,071
|
|
|
16,317,869
|
|
|
12,490,260
|
|
Other expense
(income)
|
|
|
328,461
|
|
|
212,426
|
|
|
399,182
|
|
|
559,299
|
|
Income (loss) before
taxes
|
|
|
(30,709,911)
|
|
|
(8,853,408)
|
|
|
(48,490,799)
|
|
|
(419,648,713)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense
(benefit)
|
|
|
(2,998,554)
|
|
|
1,805,176
|
|
|
(5,067,084)
|
|
|
13,090,905
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
(loss)
|
|
|
(27,711,357)
|
|
|
(10,658,584)
|
|
|
(43,423,715)
|
|
|
(432,739,618)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Less: net income
(loss) attributable to noncontrolling interests
|
|
|
3,906,540
|
|
|
4,093,593
|
|
|
2,362,899
|
|
|
(7,959,172)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
attributable to Nutex Health Inc.
|
|
$
|
(31,617,897)
|
|
$
|
(14,752,177)
|
|
$
|
(45,786,614)
|
|
$
|
(424,780,446)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per
common share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
(0.05)
|
|
|
(0.02)
|
|
|
(0.07)
|
|
|
(0.67)
|
|
Diluted
|
|
|
(0.05)
|
|
|
(0.02)
|
|
|
(0.07)
|
|
|
(0.67)
|
|
NUTEX HEALTH
INC.
|
|
CONSOLIDATED
STATEMENTS OF CASH FLOWS
|
|
(Unaudited)
|
|
|
|
Year ended
December 31,
|
|
|
2023
|
|
2022
|
|
2021
|
|
Cash flows from
operating activities:
|
|
|
|
|
|
|
|
|
|
|
Net income
(loss)
|
|
$
|
(43,423,715)
|
|
$
|
(432,739,618)
|
|
$
|
168,525,285
|
|
Adjustment to reconcile
net income (loss) to net cash from operating activities:
|
|
|
|
|
|
|
|
|
|
|
Depreciation and
amortization
|
|
|
17,591,572
|
|
|
13,131,374
|
|
|
7,662,464
|
|
Debt accretion
expense
|
|
|
1,209,981
|
|
|
1,952,829
|
|
|
50,273
|
|
Impairment of
assets
|
|
|
29,082,203
|
|
|
-
|
|
|
-
|
|
Impairment of
goodwill
|
|
|
1,139,297
|
|
|
398,135,038
|
|
|
-
|
|
Stock-based
compensation expense
|
|
|
2,835,971
|
|
|
189,581
|
|
|
-
|
|
Rescission of warrant
exercise expense
|
|
|
-
|
|
|
561,651
|
|
|
-
|
|
Other income - gain on
PPP loan forgiveness
|
|
|
-
|
|
|
-
|
|
|
(5,546,597)
|
|
Deferred tax expense
(benefit)
|
|
|
(5,707,323)
|
|
|
4,996,209
|
|
|
-
|
|
(Gain) loss on lease
termination
|
|
|
58,210
|
|
|
-
|
|
|
(109,494)
|
|
Non-cash lease
expense
|
|
|
131,582
|
|
|
64,143
|
|
|
97,578
|
|
Changes in operating
assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
(969,761)
|
|
|
56,622,133
|
|
|
(5,392,614)
|
|
Accounts
receivable - related party
|
|
|
(3,613,885)
|
|
|
1,454,934
|
|
|
(1,229,940)
|
|
Inventories
|
|
|
142,701
|
|
|
(719,107)
|
|
|
(1,088,489)
|
|
Prepaid
expenses and other current assets
|
|
|
(817,297)
|
|
|
(1,419,139)
|
|
|
(233,114)
|
|
Accounts
payable
|
|
|
(4,715,101)
|
|
|
10,018,100
|
|
|
6,365,978
|
|
Accounts
payable - related party
|
|
|
2,466,536
|
|
|
(329,155)
|
|
|
(97,985)
|
|
Accrued
expenses and other current liabilities
|
|
|
5,845,481
|
|
|
(1,311,865)
|
|
|
4,429,141
|
|
Net cash from
operating activities
|
|
|
1,256,452
|
|
|
50,607,108
|
|
|
173,432,486
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from
investing activities:
|
|
|
|
|
|
|
|
|
|
|
Acquisitions of
property and equipment
|
|
|
(9,496,832)
|
|
|
(14,632,414)
|
|
|
(36,926,591)
|
|
Acquired cash in
reverse acquisition with Clinigence
|
|
|
-
|
|
|
12,716,228
|
|
|
-
|
|
Payments for
acquisitions of businesses, net of cash acquired
|
|
|
(703,893)
|
|
|
-
|
|
|
-
|
|
Cash related to
deconsolidation of Real Estate Entities
|
|
|
(1,039,157)
|
|
|
(2,421,212)
|
|
|
(48,853)
|
|
Net cash from
investing activities
|
|
|
(11,239,882)
|
|
|
(4,337,398)
|
|
|
(36,975,444)
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from
financing activities:
|
|
|
|
|
|
|
|
|
|
|
Proceeds from lines of
credit
|
|
|
2,340,911
|
|
|
2,623,479
|
|
|
-
|
|
Proceeds from notes
payable
|
|
|
16,952,905
|
|
|
815,881
|
|
|
19,614,372
|
|
Proceeds from
convertible notes
|
|
|
4,909,864
|
|
|
-
|
|
|
-
|
|
Repayments of lines of
credit
|
|
|
(1,592,714)
|
|
|
(72,055)
|
|
|
(864,659)
|
|
Repayments of notes
payable
|
|
|
(16,479,512)
|
|
|
(7,237,094)
|
|
|
(20,715,235)
|
|
Repayments of finance
leases
|
|
|
(3,484,683)
|
|
|
(1,721,224)
|
|
|
(1,255,486)
|
|
Payment of debt
issuance costs
|
|
|
-
|
|
|
-
|
|
|
(47,875)
|
|
Rescission of warrant
exercise
|
|
|
-
|
|
|
(588,042)
|
|
|
-
|
|
Common stock issued for
exercise of warrants
|
|
|
-
|
|
|
4,119,141
|
|
|
-
|
|
Common stock issued for
exercise of options
|
|
|
-
|
|
|
644,974
|
|
|
-
|
|
Members'
contributions
|
|
|
298,032
|
|
|
4,513,867
|
|
|
21,753,773
|
|
Members'
distributions
|
|
|
(5,214,581)
|
|
|
(51,231,657)
|
|
|
(144,337,923)
|
|
Net cash from
financing activities
|
|
|
(2,269,778)
|
|
|
(48,132,730)
|
|
|
(125,853,033)
|
|
Net change in cash and
cash equivalents
|
|
|
(12,253,208)
|
|
|
(1,863,020)
|
|
|
10,604,009
|
|
Cash and cash
equivalents - beginning of the year
|
|
|
34,255,264
|
|
|
36,118,284
|
|
|
25,514,275
|
|
Cash and cash
equivalents - end of the year
|
|
$
|
22,002,056
|
|
$
|
34,255,264
|
|
$
|
36,118,284
|
Non-GAAP Financial Measures (Unaudited)
Adjusted EBITDA. Adjusted EBITDA is used as a
supplemental non-GAAP financial measure by management and external
users of our financial statements, such as industry analysts,
investors, lenders and rating agencies. We believe Adjusted EBITDA
is useful because it allows us to more effectively evaluate our
operating performance.
We define Adjusted EBITDA as net income (loss) attributable to
Nutex Health Inc. plus net interest expense, income taxes,
depreciation and amortization, further adjusted for stock-based
compensation, certain defined items of expense, any
acquisition-related costs and impairments. A reconciliation of net
income to Adjusted EBITDA is included below. Adjusted EBITDA is not
intended to serve as an alternative to U.S. GAAP measures of
performance and may not be comparable to similarly-titled measures
presented by other companies.
|
|
Year ended
December 31,
|
|
|
2023
|
|
2022
|
|
2021
|
|
Reconciliation of net
income (loss) attributable to Nutex Health
Inc. to Adjusted EBITDA:
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
attributable to Nutex Health Inc.
|
|
$
|
(45,786,614)
|
|
$
|
(424,780,446)
|
|
$
|
132,593,328
|
|
Depreciation and
amortization
|
|
|
17,591,572
|
|
|
13,131,374
|
|
|
7,662,464
|
|
Interest expense,
net
|
|
|
16,317,869
|
|
|
12,490,260
|
|
|
6,196,026
|
|
Income tax
expense
|
|
|
(5,067,084)
|
|
|
13,090,905
|
|
|
965,731
|
|
Allocation to
noncontrolling interests
|
|
|
(5,546,263)
|
|
|
(4,837,514)
|
|
|
(5,751,066)
|
|
EBITDA
|
|
|
(22,490,520)
|
|
|
(390,905,421)
|
|
|
141,666,483
|
|
Facility closing
costs
|
|
|
217,266
|
|
|
-
|
|
|
-
|
|
Acquisition
costs
|
|
|
43,464
|
|
|
3,885,666
|
|
|
3,553,716
|
|
Stock-based
compensation
|
|
|
2,835,971
|
|
|
189,581
|
|
|
-
|
|
Rescission of warrant
exercise
|
|
|
-
|
|
|
1,243,059
|
|
|
-
|
|
Impairment of
assets
|
|
|
29,082,203
|
|
|
-
|
|
|
-
|
|
Impairment of
goodwill
|
|
|
1,139,297
|
|
|
398,135,038
|
|
|
-
|
|
Adjusted
EBITDA
|
|
$
|
10,827,681
|
|
$
|
12,547,923
|
|
$
|
145,220,199
|
|
|
Three months ended
|
|
Three months ended
|
|
|
December 31, 2023
|
|
December 31, 2022
|
|
|
Unaudited
|
|
Unaudited
|
|
Reconciliation of net
income (loss) attributable to Nutex Health Inc. to
Adjusted EBITDA:
|
|
|
|
|
|
|
|
Net loss attributable
to Nutex Health Inc.
|
|
$
|
(31,617,897)
|
|
$
|
(14,752,177)
|
|
Depreciation and
amortization
|
|
|
4,682,724
|
|
|
3,271,861
|
|
Interest expense,
net
|
|
|
4,236,553
|
|
|
2,862,071
|
|
Income tax
expense
|
|
|
(2,998,554)
|
|
|
1,805,176
|
|
Allocation to
noncontrolling interests
|
|
|
(2,045,390)
|
|
|
(392,290)
|
|
EBITDA
|
|
|
(27,742,564)
|
|
|
(7,205,359)
|
|
Stock-based
compensation
|
|
|
637,159
|
|
|
54,166
|
|
Rescission of warrant
exercise
|
|
|
-
|
|
|
1,243,059
|
|
Impairment of
assets
|
|
|
29,082,203
|
|
|
-
|
|
Impairment of
goodwill
|
|
|
1,139,297
|
|
|
-
|
|
Adjusted
EBITDA
|
|
$
|
3,116,095
|
|
$
|
(5,908,134)
|
About Nutex Health Inc.
Headquartered in Houston, Texas
and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a
healthcare management and operations company with two divisions: a
Hospital Division and a Population Health Management Division.
The Hospital Division owns, develops and operates innovative
health care models, including micro-hospitals, specialty hospitals,
and hospital outpatient departments (HOPDs). This division owns and
operates 20 facilities in 8 states.
The Population Health Management division owns and operates
provider networks such as Independent Physician Associations
(IPAs). Through our Management Services Organization (MSO), we
provide management, administrative and other support services to
our affiliated hospitals and physician groups. Our
cloud-based proprietary technology platform aggregates clinical and
claims data across multiple settings, information systems and
sources to create a holistic view of patients and providers,
allowing us to deliver greater quality care more
efficiently.
Forward-Looking Statements
Certain statements and information included in this press
release constitute "forward-looking statements" within the meaning
of the Private Securities Litigation Act of 1995. When used in this
press release, the words or phrases "will", "will likely result,"
"expected to," "will continue," "anticipated," "estimate,"
"projected," "intend," "goal," or similar expressions are intended
to identify "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to certain risks, known and unknown, and uncertainties,
many of which are beyond the control of the Company. Such
uncertainties and risks include, but are not limited to, our
ability to successfully execute our growth strategy, changes in
laws or regulations, including the interim final and final rules
implemented under the No Surprises Act , economic conditions,
dependence on management, dilution to stockholders, lack of
capital, the effects of rapid growth upon the Company and the
ability of management to effectively respond to the growth and
demand for products and services of the Company, newly developing
technologies, the Company's ability to compete, conflicts of
interest in related party transactions, regulatory matters,
protection of technology, lack of industry standards, the effects
of competition and the ability of the Company to obtain future
financing. An extensive list of factors that can affect future
results are discussed in the Annual Report on Form 10-K for the
year ended December 31, 2023 under
the heading "Risk Factors" in Part I, Item IA thereof, and other
documents filed from time to time with the Securities and Exchange
Commission. Such factors could materially adversely affect the
Company's financial performance and could cause the Company's
actual results for future periods to differ materially from any
opinions or statements expressed within this press release.
View original
content:https://www.prnewswire.com/news-releases/nutex-health-reports-fourth-quarter-and-full-year-2023-financial-results-302103192.html
SOURCE Nutex Health, Inc.